Global biopharma CEOs and top executives are taking part in a virtual briefing on COVID-19.
The briefing is being organised by the International Federation of Pharmaceutical Manufacturers and Associations, representing the world’s leading biopharmaceutical companies.
On 2 December, the UK became the first country in the world to grant approval to emergency use of a candidate vaccine produced by US pharmaceutical giant Pfizer and German firm BioNTech, and the second to register an anti-COVID vaccine. In August, Russia became the first country to register a COVID-19 vaccine, which was named Sputnik V. The clinical trials of the Sputnik V vaccine, developed by the Gamaleya research institute, have demonstrated that its efficacy rate is above 90 percent. Dozens of countries have already expressed their interest in procuring the Russian vaccine.
Follow Sputnik feed to find out more.
